Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Division of Internal Medicine, Rochester General Hospital, New York.
Clin Infect Dis. 2018 Feb 1;66(4):514-522. doi: 10.1093/cid/cix833.
The choice of antibiotics for systemic infections in patients with a high risk of Clostridium difficile infection (CDI) remains a clinical practice dilemma. Although some studies suggest that tetracyclines may be associated with a lower risk of CDI than other antibiotics, other results are conflicting. We conducted a systematic review and metaanalysis of studies that assessed the risk of CDI with tetracyclines compared to other antibiotics.
We conducted a systematic search of Medline, Embase, and Web of Science from January 1978 through December 2016 to include studies that assessed the association between tetracycline use and risk of CDI. Weighted summary estimates were calculated using generalized inverse variance with a random-effects model using RevMan 5.3. Study quality was assessed using the Newcastle-Ottawa scale.
Six studies (4 case control, 2 cohort) with patient recruitment between 1993 and 2012 were included. Metaanalysis using a random-effects model, demonstrated that tetracyclines were associated with a decreased risk of CDI (odds ratio [OR], 0.62; 95% confidence interval [CI], 0.47-0.81; P < .001). There was significant heterogeneity, with an I2 of 53% with no publication bias. Subgroup analysis of studies that evaluated the risk of CDI with doxycycline alone also demonstrated a decreased risk of CDI (OR, 0.55; 95% CI, 0.40-0.75; P < .001).
Metaanalyses of existing studies suggest that tetracyclines may be associated with a decreased risk of CDI compared with other antimicrobials. It may be reasonable to use tetracyclines whenever appropriate to decrease CDI associated with antibiotic use.
对于有较高艰难梭菌感染(CDI)风险的患者,全身感染的抗生素选择仍然是临床实践中的一个难题。尽管一些研究表明,与其他抗生素相比,四环素类药物可能与较低的 CDI 风险相关,但其他结果却存在矛盾。我们对评估四环素类药物与其他抗生素相比 CDI 风险的研究进行了系统回顾和荟萃分析。
我们对 Medline、Embase 和 Web of Science 进行了系统检索,检索时间从 1978 年 1 月到 2016 年 12 月,纳入评估四环素类药物使用与 CDI 风险之间关系的研究。使用随机效应模型和广义逆方差法计算加权汇总估计值,使用 RevMan 5.3 进行分析。使用 Newcastle-Ottawa 量表评估研究质量。
纳入的 6 项研究(4 项病例对照,2 项队列研究)的患者招募时间为 1993 年至 2012 年。使用随机效应模型进行荟萃分析显示,四环素类药物与 CDI 风险降低相关(比值比 [OR],0.62;95%置信区间 [CI],0.47-0.81;P <.001)。存在显著的异质性,I2 为 53%,不存在发表偏倚。对评估单独使用多西环素的 CDI 风险的研究进行亚组分析,也显示 CDI 风险降低(OR,0.55;95% CI,0.40-0.75;P <.001)。
对现有研究的荟萃分析表明,与其他抗菌药物相比,四环素类药物可能与 CDI 风险降低相关。在适当情况下使用四环素类药物以降低与抗生素使用相关的 CDI 可能是合理的。